One of the important outcomes of the meeting was fast tracking of approvals for registration of Indian pharmaceutical products already registered by USFDA, UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) and European Medicines Agency (EMA) during the deliberations.
Other outcomes include, joint release of a market research report commissioned by the embassy of India, Muscat on the pharmaceutical sector in Oman, highlighting strategies and opportunities for Indian companies in that country.
“Expression of commitment from both sides to facilitate trade and to comprehensively address all issues pertaining to tariff/non-tariff barriers. Agreement on expeditious conclusion of all MoUs/Agreements under discussion, including on standards and metrology, India-Oman Double Taxation Avoidance Agreement, India-Oman Bilateral Investment Treaty, Invest Oman and Invest India, and Rupay card acceptance in Oman etc,” the statement stated these as the outcomes.